Japan Tobacco Is First Customer for Gene Logic's Database

COLUMBIA, Md.--Gene Logic here has announced that it will collaborate with Japan Tobacco to uncover drug targets and leads in kidney disease. Gene Logic will utilize its proprietary Accelerated Drug Discovery platform in the effort. Japan Tobacco will also be the first subscriber to Gene Logic's Gene Express Normal database of quantitative gene expression profiles in a variety of normal tissues of human, rat, and mouse origin. The deal also gives Japan Tobacco the option of accessing Gene Logic's Flow-thru Gene Chip technology for high-throughput screening.